Introduction: Cancer treatment in the Unified Health System SUS is carried out, preferably in hospitals qualified as High Complexity Oncology Units and High Complexity Oncology Assistance Centers. In the state, the large territorial extension and the concentration of services in a few municipalities can generate significant geographic barriers to access.Objectives: Analyze the distance between the municipalities of Pará and hospitals qualified for oncological treatment. Methods: This is a descriptive, cross-sectional ecological study, based on public secondary data. The 144 municipalities of Para were analyzed. The presence of qualified hospitals was verified through the Access Protocol to the medium and high complexity oncology care network in the state of Para. For each municipality without a license, the road distance to the nearest hospital was calculated using Google Maps. The dictatorships were grouped into bands of up to 50 km, between 51–100 km, between 101–200 km and over 200 km. Results: Of the 144 municipalities in Pará, only 10 (7%) are within 50 km of a hospital qualified for oncology treatment. Another 22 municipalities (15%) are located between 51 and 100 km. The majority are between 101 and 200 km (53 municipalities, 37%) or more than 200 km (58 municipalities, 40%). This means that more than three quarters of the state’s municipalities are more than 100 km away from a specialized oncology service. The physical distance to the oncology treatment service represents a real barrier for a large part of the population of Pará, especially those who live in inland, riverside and difficult-to-access regions. Prolonged travel can compromise the timely initiation of treatment, increase transportation and accommodation costs, and negatively impact adherence and clinical outcomes. In a state with continental dimensions and low density of services, inequality in access to oncology care worsens, requiring more efficient regional strategies.Conclusion:The analysis revealed a concentration of oncology services enabled in a few urban centers in Pará, generating high distances for most municipalities. These findings reinforce the importance of regionalizing cancer care in the SUS, with the expansion of enabled services and the implementation of measures to support the movement of patients in remote regions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
